安进公司表示，已聘请一家独立学术机构重新评估其一款罕见病药物的数据。
据 Bloomberg 报道，美国监管机构正试图将该药物撤出市场。
安进委托独立学术机构复核罕见病药数据
2026-06-11 21:16:47
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
芝商所将扩大WTI原油与黄金全天候交易时段
